Remicade Biosimilars Market Size & Share to Exceed USD 34.4 Billion by 2034, at CAGR of 9.30% - By PMI
08 févr. 2024 17h30 HE
|
PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of...
Monoclonal Antibody Diagnostic Reagents Market Size & Share to Exceed USD 27.2 Billion by 2034, at CAGR of 12.30% – By PMI
08 févr. 2024 15h30 HE
|
PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Monoclonal Antibody Diagnostic Reagents Market size was valued at about USD 8.5 Billion in 2024 and expected to...
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
05 févr. 2024 08h00 HE
|
Rani Therapeutics, LLC
- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111...
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
05 juin 2023 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
16 mars 2023 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...